Reported 3 days ago
Rocket Pharmaceuticals' stock surged 5.5% after Jefferies initiated coverage with a 'buy' rating, citing optimism over its gene therapy pipeline, particularly for a treatment addressing Danon heart disease. With a price target set at $29, analysts highlighted the potential $1 billion market opportunity for Rocket, although the stock had previously declined nearly 60% in 2024.
Source: YAHOO